1800-272-662
Shopping Cart 0
countryflagAU
Login

Medpace Holdings Inc

Healthcare US MEDP

466.79USD
-11.75(2.46%)

Last update at 2026-03-10T20:00:00Z

Day Range

463.32479.31
LowHigh

52 Week Range

286.75459.77
LowHigh

Fundamentals

  • Previous Close 478.54
  • Market Cap10485.38M
  • Volume326983
  • P/E Ratio29.49
  • Dividend Yield-%
  • EBITDA437.53M
  • Revenue TTM2070.87M
  • Revenue Per Share TTM67.02
  • Gross Profit TTM 1392.00M
  • Diluted EPS TTM11.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 282.86M 201.85M 168.53M 124.83M 93.95M
Minority interest - - - - -
Net income 245.37M 181.85M 145.38M 100.44M 73.19M
Selling general administrative 131.40M 108.42M 92.16M 95.25M 75.68M
Selling and marketing expenses - - - - -
Gross profit 432.44M 328.15M 278.73M 245.70M 215.53M
Reconciled depreciation 22.34M 21.12M 19.53M 23.19M 38.80M
Ebit 278.70M 198.62M 167.04M 127.26M 102.11M
Ebitda 301.04M 219.73M 186.57M 150.45M 140.91M
Depreciation and amortization 22.34M 21.12M 19.53M 23.19M 38.80M
Non operating income net other 7.07M 3.34M 1.18M -0.86300M 1.06M
Operating income 278.70M 198.62M 167.04M 127.26M 101.05M
Other operating expenses 1181.30M 943.76M 758.88M 733.71M 603.54M
Interest expense 2.90M -0.10500M 0.31M 1.57M 8.16M
Tax provision 37.49M 20.00M 23.15M 24.39M 20.77M
Interest income - - - 1.57M 8.16M
Net interest income -2.90500M -0.10500M 0.31M -1.56800M -8.15700M
Extraordinary items - - - - 0.10M
Non recurring - - - - -
Other items - - - - -
Income tax expense 37.49M 20.00M 23.15M 24.39M 20.77M
Total revenue 1460.00M 1142.38M 925.92M 860.97M 704.59M
Total operating expenses 153.74M 129.54M 111.68M 118.43M 114.48M
Cost of revenue 1027.56M 814.22M 647.20M 615.27M 489.06M
Total other income expense net 4.16M 3.24M 1.49M -2.43100M 1.06M
Discontinued operations - - - - -
Net income from continuing ops 245.37M 181.85M 145.38M 100.44M 73.19M
Net income applicable to common shares 245.37M 181.85M 145.38M 100.16M 72.89M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1656.83M 1352.49M 1659.93M 1390.68M 1143.07M
Intangible assets 35.81M 38.01M 41.36M 46.47M 54.35M
Earning assets - - - - -
Other current assets 49.98M 52.29M 43.18M 34.92M 29.45M
Total liab 1097.88M 966.11M 707.01M 584.90M 416.79M
Total stockholder equity 558.95M 386.39M 952.93M 805.78M 726.28M
Deferred long term liab - 1.07M 1.08M 13.55M 12.85M
Other current liab 40.44M 257.67M 27.61M 23.53M 18.99M
Common stock 0.31M 0.31M 0.36M 0.35M 0.36M
Capital stock 0.31M 0.31M 0.36M 0.35M 0.36M
Retained earnings -221.64500M -359.82700M 234.98M 115.23M 68.11M
Other liab - 23.77M 18.82M 29.64M 28.57M
Good will 662.40M 662.40M 662.40M 662.40M 662.40M
Other assets - 69.21M 42.56M 123.14M 9.85M
Cash 245.45M 28.27M 461.30M 277.77M 131.92M
Cash and equivalents - - - - -
Total current liabilities 925.13M 803.47M 557.22M 440.11M 343.00M
Current deferred revenue 559.86M 462.73M 344.64M 255.66M 192.36M
Net debt -103.32700M 160.60M -330.33900M -162.62300M -86.70800M
Short term debt 292.96M 50.00M 159.29M 134.37M 109.25M
Short long term debt - 50.00M - - -
Short long term debt total 142.12M 188.87M 130.97M 115.14M 45.21M
Other stockholder equity 790.36M 758.30M 722.43M 690.33M 660.55M
Property plant equipment - 109.85M 93.15M 85.02M 99.44M
Total current assets 593.83M 333.96M 690.91M 473.65M 317.03M
Long term investments - - - - -
Net tangible assets - -314.01700M 249.17M 96.91M 9.54M
Short term investments - - - - -
Net receivables 298.40M 253.40M 186.43M 160.96M 155.66M
Long term debt - - - - -
Inventory 0.00000M - - - -
Accounts payable 31.87M 33.07M 25.68M 26.55M 22.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -10.07200M -12.39200M -4.84600M -0.13100M -2.74100M
Additional paid in capital - - - - -
Common stock total equity - 0.31M 0.36M 0.35M 0.36M
Preferred stock total equity - - - - -
Retained earnings total equity - -359.82700M 234.98M 115.23M 68.11M
Treasury stock - -12.49700M -5.42700M -5.57800M -6.03000M
Accumulated amortization - - - - -
Non currrent assets other 24.97M 21.13M 17.42M 8.79M 9.48M
Deferred long term asset charges - - - - 0.38M
Non current assets total 1063.00M 1018.53M 969.02M 917.03M 826.04M
Capital lease obligations 142.12M 138.87M 130.97M 115.14M 45.21M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -38.74200M -31.36400M -31.21400M -19.14400M -16.97300M
Change to liabilities 58.91M 28.02M 21.63M 26.55M 30.37M
Total cashflows from investing activities -38.74200M -31.36400M -31.21400M -19.14400M -16.97300M
Net borrowings 50.00M 50.00M 50.00M -80.43800M -144.06900M
Total cash from financing activities -775.77500M -44.45300M -82.28200M -73.91800M -141.58000M
Change to operating activities 48.46M 0.85M 10.98M 7.53M 29.71M
Net income 245.37M 181.85M 145.38M 100.44M 73.19M
Change in cash -433.03900M 183.54M 145.85M 108.64M -3.21000M
Begin period cash flow 461.30M 277.77M 131.92M 23.28M 26.49M
End period cash flow 28.27M 461.30M 277.77M 131.92M 23.28M
Total cash from operating activities 388.05M 263.33M 258.68M 201.87M 156.58M
Issuance of capital stock - - - - 0.00000M
Depreciation 22.34M 21.12M 19.53M 23.19M 38.80M
Other cashflows from investing activities -1.86300M -3.09300M 0.13M -1.23200M -0.94900M
Dividends paid - - - - -
Change to inventory - 24.98M 5.53M 21.26M 27.79M
Change to account receivables -66.92000M -24.98200M -5.53000M -21.25600M -27.04700M
Sale purchase of stock -847.84900M -62.09600M -98.27400M 6.52M 2.49M
Other cashflows from financing activities 346.27M 17.64M 15.99M 6.52M 0.61M
Change to netincome -3.10900M -21.96700M 14.29M 32.55M 12.09M
Capital expenditures 36.88M 28.27M 31.34M 17.91M 16.02M
Change receivables -66.92000M -24.98200M -5.53000M -21.25600M -27.04700M
Cash flows other operating 131.46M 79.29M 63.37M 39.44M 28.57M
Exchange rate changes - - - - -
Cash and cash equivalents changes -426.46700M 187.51M 145.18M 108.81M -1.96900M
Change in working capital 106.06M 66.71M 66.26M 35.59M 39.60M
Stock based compensation 21.41M 14.47M 13.78M 20.74M 6.50M
Other non cash items 15.89M 16.30M 13.20M 11.86M -5.44400M
Free cash flow 351.17M 235.06M 227.34M 183.96M 140.56M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MEDP
Medpace Holdings Inc		 -11.75 2.46% 466.79 29.49 25.91 5.06 11.90 4.81 22.76
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings Inc

5375 Medpace Way, Cincinnati, OH, United States, 45227

Key Executives

Name Title Year Born
Dr. August James Troendle M.D. Chairman & CEO 1956
Mr. Jesse J. Geiger BBA, CPA Pres 1974
Mr. Kevin M. Brady CFO & Treasurer 1974
Ms. Susan E. Burwig Exec. VP of Operations 1963
Mr. Stephen P. Ewald Chief Compliance Officer, Gen. Counsel & Corp. Sec. 1969
Brandon Ebken Chief Information Officer NA
Ms. Lauren Morris Associate Director of Investors Relations NA
Mr. Todd Meyers VP of Bus. Devel. & Marketing NA
Mr. Weimin Gai MS Sr. VP of Biometrics NA
Mr. Daniel O'Leary Sr. VP of Medical Department NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.